Blau综合征诊疗专家共识（2024版）

doi:10.35541/cjd.20230514

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (11): 1004-1010.doi: 10.35541/cjd.20230514

Blau综合征诊疗专家共识（2024版）

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

收稿日期:2023-09-06 修回日期:2024-08-14 发布日期:2024-10-31
通讯作者: 高兴华; 耿松梅 E-mail:gaobarry@hotmail.com; gengsongmei73@ 163.com

Expert consensus on diagnosis and treatment of Blau syndrome （2024）

Chinese Society of Dermatology; China Dermatologist Association

Chinese Society of Dermatology; China Dermatologist Association

Received:2023-09-06 Revised:2024-08-14 Published:2024-10-31
Contact: Gao Xinghua; Geng Songmei E-mail:gaobarry@hotmail.com; gengsongmei73@ 163.com

摘要/Abstract

摘要： 【摘要】 Blau综合征是一种罕见的单基因突变导致的自身炎症性疾病，以皮疹、肉芽肿性多关节炎和葡萄膜炎的三联征为主要临床特征，可累及多系统，造成严重并发症，影响患者生活质量。中华医学会皮肤性病学分会、中国医师协会皮肤科医师分会组织多学科专家在综述国内外文献的基础上，结合我国诊疗现状，综合多学科专家意见，形成Blau综合征诊疗专家共识，重点阐述Blau综合征的临床表现、诊断、严重程度评估及治疗，为临床规范化诊疗提供参考依据。

关键词: Blau综合征, 诊断, 治疗, 专家共识

Abstract: 【Abstract】 Blau syndrome is a rare autoinflammatory disease caused by monogenic mutations, characterized by a triad of rashes, granulomatous polyarthritis and uveitis. It can affect multiple systems, leading to serious complications that impact patients' quality of life. The Chinese Society of Dermatology and the China Dermatologist Association organized multidisciplinary experts to develop a consensus on the diagnosis and treatment of Blau syndrome based on Chinese and international literature, the current status of its diagnosis and treatment in China and experts' opinions. This consensus focuses on the clinical manifestations, diagnosis, assessment of severity, and treatment of Blau syndrome, aiming to provide a reference for standardized diagnosis and treatment in clinical practice.

Key words: Blau syndrome, Diagnosis, Treatment, Expert consensus

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. Blau综合征诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(11):1004-1010. doi:10.35541/cjd.20230514

Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on diagnosis and treatment of Blau syndrome （2024）[J]. Chinese Journal of Dermatology, 2024, 57(11): 1004-1010.doi:10.35541/cjd.20230514

参考文献 49

［1］	Kaufman KP, Becker ML. Distinguishing Blau syndrome from systemic sarcoidosis［J］. Curr Allergy Asthma Rep, 2021,21（2）:10. doi: 10.1007/s11882⁃021⁃00991⁃3.
［2］	Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis［J］. N Engl J Med, 2007,357（21）:2153⁃2165. doi: 10.1056/NEJMra071714.
［3］	Chiu B, Chan J, Das S, et al. Pediatric sarcoidosis: a review with emphasis on early onset and high⁃risk sarcoidosis and diagnostic challenges［J］. Diagnostics （Basel）, 2019,9（4）:160. doi: 10. 3390/diagnostics9040160.
［4］	Blau EB. Familial granulomatous arthritis, iritis, and rash［J］. J Pediatr, 1985,107（5）:689⁃693. doi: 10.1016/s0022⁃3476（85）80394⁃2.
［5］	张俊梅, 赵晓珍, 唐雪梅, 等. 中国儿童Blau综合征临床特点和治疗分析⁃全国多中心研究［J］. 罕见病研究, 2022,1（3）:252⁃258. doi: 10.12376/j.issn.2097⁃0501.2022.03.005.
［6］	Rosé CD, Pans S, Casteels I, et al. Blau syndrome: cross⁃sectional data from a multicentre study of clinical, radiological and functional outcomes［J］. Rheumatology （Oxford）, 2015,54（6）:1008⁃1016. doi: 10.1093/rheumatology/keu437.
［7］	Miceli⁃Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome［J］. Nat Genet, 2001,29（1）:19⁃20. doi: 10.1038/ng720.
［8］	Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto⁃inflammatory granulomatous disease［J］. Pediatr Rheumatol Online J, 2014,12:33. doi: 10.1186/1546⁃0096⁃12⁃33.
［9］	Kanazawa N, Okafuji I, Kambe N, et al. Early⁃onset sarcoidosis and CARD15 mutations with constitutive nuclear factor⁃kappaB activation: common genetic etiology with Blau syndrome［J］. Blood, 2005,105（3）:1195⁃1197. doi: 10.1182/blood⁃2004⁃07⁃2972.
［10］	Tangye SG, Al⁃Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee［J］. J Clin Immunol, 2022,42（7）:1473⁃1507. doi: 10.1007/s10875⁃022⁃01289⁃3.
［11］	Aróstegui JI, Arnal C, Merino R, et al. NOD2 gene⁃associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin⁃1 blockade in a Spanish cohort［J］. Arthritis Rheum, 2007,56（11）:3805⁃3813. doi: 10.1002/art.22966.
［12］	Rosé CD, Aróstegui JI, Martin TM, et al. NOD2⁃associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain［J］. Arthritis Rheum, 2009,60（6）:1797⁃1803. doi: 10.1002/art. 24533.
［13］	Sarens IL, Casteels I, Anton J, et al. Blau syndrome⁃associated uveitis: preliminary results from an international prospective interventional case series［J］. Am J Ophthalmol, 2018,187:158⁃166. doi: 10.1016/j.ajo.2017.08.017.
［14］	Matsuda T, Kambe N, Ueki Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation［J］. Ann Rheum Dis, 2020,79（11）:1492⁃1499. doi: 10.1136/annrheumdis⁃2020⁃217320.
［15］	Opitz B, Püschel A, Schmeck B, et al. Nucleotide⁃binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae［J］. J Biol Chem, 2004,279（35）:36426⁃36432. doi: 10.1074/jbc.M403861200.
［16］	Theivanthiran B, Batra S, Balamayooran G, et al. NOD2 signaling contributes to host defense in the lungs against Escherichia coli infection［J］. Infect Immun, 2012,80（7）:2558⁃2569. doi: 10.1128/IAI.06230⁃11.
［17］	Arakawa A, Kambe N, Nishikomori R, et al. NOD2 mutation⁃associated case with Blau syndrome triggered by BCG vaccination［J］. Children （Basel）, 2021,8（2）:117. doi: 10.3390/children8020117.
［18］	Poline J, Fogel O, Pajot C, et al. Early⁃onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndrome［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:340⁃348. doi: 10.1111/jdv.15963.
［19］	Dow CT, Ellingson JL. Detection of Mycobacterium avium ss. Paratuberculosis in Blau syndrome tissues［J］. Autoimmune Dis, 2010,2011:127692. doi: 10.4061/2010/127692.
［20］	Okazaki F, Wakiguchi H, Korenaga Y, et al. A novel mutation in early⁃onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes［J］. Pediatr Rheumatol Online J, 2021,19（1）:18. doi: 10.1186/s12969⁃021⁃00505⁃5.
［21］	Caso F, Galozzi P, Costa L, et al. Autoinflammatory granulomatous diseases: from Blau syndrome and early⁃onset sarcoidosis to NOD2⁃mediated disease and Crohn's disease［J］. RMD Open, 2015,1（1）:e000097. doi: 10.1136/rmdopen⁃2015⁃000097.
［22］	Saini SK, Rose CD. Liver involvement in familial granulomatous arthritis （Blau syndrome）［J］. J Rheumatol, 1996,23（2）:396⁃399.
［23］	Inoue Y, Kawaguchi Y, Shimojo N, et al. A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early⁃onset sarcoidosis?［J］. Mod Rheumatol, 2013,23（4）:837⁃839. doi: 10.1007/s10165⁃012⁃0720⁃z.
［24］	Yotsumoto S, Takahashi Y, Takei S, et al. Early onset sarcoidosis masquerading as juvenile rheumatoid arthritis［J］. J Am Acad Dermatol, 2000,43（5 Pt 2）:969⁃971. doi: 10.1067/mjd.2000.103754.
［25］	Bittar M, Agarwal S. Sacroiliac involvement in Blau syndrome［J］. Joint Bone Spine, 2021,88（2）:105103. doi: 10.1016/j.jbspin.2020.105103.
［26］	Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis［J］. Autoimmun Rev, 2014,13（12）:1220⁃1229. doi: 10.1016/j.autrev.2014.08.010.
［27］	Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects［J］. Autoimmun Rev, 2012,12（1）:44⁃51. doi: 10.1016/j.autrev.2012.07.028.
［28］	Suresh S, Tsui E. Ocular manifestations of Blau syndrome［J］. Curr Opin Ophthalmol, 2020,31（6）:532⁃537. doi: 10.1097/ICU.0000000000000705.
［29］	郑义, 贾韬, 延聪, 等. 8例Blau综合征/早发型结节病临床表现、病理特征及基因突变的多样性分析［J］. 罕见病研究, 2023,2（2）:170⁃177. doi: 10.12376/j.issn.2097⁃0501.2023.02. 005.
［30］	Li HX, Liu ZM, Zhao SJ, et al. Measuring both procalcitonin and C⁃reactive protein for a diagnosis of sepsis in critically ill patients［J］. J Int Med Res, 2014,42（4）:1050⁃1059. doi: 10.1177/0300060514528483.
［31］	Mizuno K, Nguyen CT, Ueda⁃Hayakawa I, et al. Annular lesions of cutaneous sarcoidosis with granulomatous vasculitis［J］. J Cutan Pathol, 2017,44（5）:494⁃496. doi: 10.1111/cup.12912.
［32］	Thirumal Kumar D, Udhaya Kumar S, Nishaat Laeeque AS, et al. Computational model to analyze and characterize the functional mutations of NOD2 protein causing inflammatory disorder ⁃ Blau syndrome［J］. Adv Protein Chem Struct Biol, 2020,120:379⁃408. doi: 10.1016/bs.apcsb.2019.11.005.
［33］	Li C, Zhang J, Li S, et al. Gene mutations and clinical phenotypes in Chinese children with Blau syndrome［J］. Sci China Life Sci, 2017,60（7）:758⁃762. doi: 10.1007/s11427⁃017⁃9090⁃6.
［34］	Hatemi G, Uçar D, Uygunoğlu U, et al. Behçet syndrome［J］. Rheum Dis Clin North Am, 2023,49（3）:585⁃602. doi: 10.1016/j.rdc.2023.03.010.
［35］	Yao Q, Su LC, Tomecki KJ, et al. Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations［J］. J Am Acad Dermatol, 2013,68（4）:624⁃631. doi: 10.1016/j.jaad.2012.09.025.
［36］	Lassoued Ferjani H, Kharrat L, Ben Nessib D, et al. Management of Blau syndrome: review and proposal of a treatment algorithm［J］. Eur J Pediatr, 2024,183（1）:1⁃7. doi: 10.1007/s00431⁃023⁃05204⁃9.
［37］	Iriqat S, Safieh MA, Fatouleh M, et al. Blau syndrome: a case report from Palestine［J］. Pediatr Rheumatol Online J, 2021,19（1）:138. doi: 10.1186/s12969⁃021⁃00633⁃y.
［38］	Jindal AK, Pilania RK, Suri D, et al. A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: a clinical tryst with Blau syndrome over 20 years and case⁃based review［J］. Rheumatol Int, 2021,41（1）:173⁃181. doi: 10.1007/s00296⁃019⁃04316⁃6.
［39］	PaÇ Kisaarslan A, SÖzerİ B, Şahİn N, et al. Blau syndrome and early⁃onset sarcoidosis: a six case series and review of the literature［J］. Arch Rheumatol, 2020,35（1）:117⁃127. doi: 10.5606/ArchRheumatol.2020.7060.
［40］	Wu S, Zhong L, Sun Z, et al. Ocular features in Chinese patients with Blau syndrome［J］. Ocul Immunol Inflamm, 2020,28（1）:79⁃85. doi: 10.1080/09273948.2019.1569239.
［41］	Wang W, Wang W, Zhong LQ, et al. Thalidomide may be an effective drug for Blau syndrome: a case report［J］. Ann Palliat Med, 2022,11（7）:2538⁃2543. doi: 10.21037/apm⁃21⁃2216.
［42］	Mezouar S, Diarra I, Roudier J, et al. Tumor necrosis factor⁃alpha antagonist interferes with the formation of granulomatous multinucleated giant cells: new insights into Mycobacterium tuberculosis infection［J］. Front Immunol, 2019,10:1947. doi: 10.3389/fimmu.2019.01947.
［43］	Arvesen KB, Herlin T, Larsen DA, et al. Diagnosis and treatment of Blau syndrome/early⁃onset sarcoidosis, an autoinflammatory granulomatous disease, in an infant［J］. Acta Derm Venereol, 2017,97（1）:126⁃127.e7. doi: 10.2340/0001 5555⁃2485.
［44］	Naik AU, Annamalai R, Biswas J. Uveitis in sporadic Blau syndrome: long⁃term follow⁃up of a refractory case treated successfully with adalimumab［J］. Indian J Ophthalmol, 2018,66（10）:1483⁃1485. doi: 10.4103/ijo.IJO_629_18.
［45］	Millington G, Dobson J, Holden S, et al. Sporadic Blau syndrome treated with adalimumab［J］. Clin Exp Dermatol, 2019,44（7）:811⁃813. doi: 10.1111/ced.14016.
［46］	Kitagawa Y, Kawasaki Y, Yamasaki Y, et al. Anti⁃TNF treatment corrects IFN⁃γ⁃dependent proinflammatory signatures in Blau syndrome patient⁃derived macrophages［J］. J Allergy Clin Immunol, 2022,149（1）:176⁃188. doi: 10.1016/j.jaci.2021. 05. 030.
［47］	Lu L, Shen M, Jiang D, et al. Blau syndrome with good reponses to tocilizumab: a case report and focused literature review［J］. Semin Arthritis Rheum, 2018,47（5）:727⁃731. doi: 10.1016/j.semarthrit.2017.09.010.
［48］	Nagakura T, Wakiguchi H, Kubota T, et al. Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome［J］. J Rheumatol, 2017,44（4）:536⁃538. doi: 10.3899/jrheum.160672.
［49］	Zhang S, Cai Z, Mo X, et al. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients［J］. Pediatr Rheumatol Online J, 2021,19（1）:160. doi: 10.1186/s12969⁃021⁃00634⁃x.

[1]	黄淑黛王大光. 甲与甲病的皮肤影像学进展[J]. 中华皮肤科杂志, 2024, 57(9): 866-869.
[2]	郝峰刘国艳. [开放获取] 光学相干断层扫描技术在皮肤科的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 853-857.
[3]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[4]	邹先彪陈锦纯曾悦郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790.
[5]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[6]	曾悦邵惠红林诗雯温柔邹先彪. 可穿戴远程会诊设备在常见皮肤病诊断中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 797-800.
[7]	何兰马玲姜倩陈柳青陈红英. 非生殖器部位硬化性苔藓57例皮肤镜与反射式共聚焦显微镜影像特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 791-796.
[8]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[9]	中国中西医结合学会皮肤性病专业委员会中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 反射式共聚焦显微镜在常见黑素细胞性皮肤肿瘤中的应用专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(9): 775-784.
[10]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[11]	谢媛媛刘宇甄曾荣. 皮肤影像技术在寻常痤疮诊疗中的应用进展[J]. 中华皮肤科杂志, 2024, 57(8): 757-760.
[12]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[13]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[14]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.
[15]	刘青锋刘莲刁萍李晓雪张婷陈浩天刘绪蒋献. 鲜红斑痣相关综合征的诊疗进展[J]. 中华皮肤科杂志, 2024, 57(7): 656-660.

Blau综合征诊疗专家共识（2024版）

Expert consensus on diagnosis and treatment of Blau syndrome （2024）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

Metrics

本文评价

推荐阅读 10